Aligos Therapeutics, Inc.

ALGS · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
84
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARSCoV2, SARSCoV, MERSCoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development ...

Next Earnings

Q2 FY2026 — expected 2026-08-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionALGSdiscussed_in_filing Cybersecurity
topic_mentionALGSdiscussed_in_filing Cybersecurity
topic_mentionALGSdiscussed_in_filing Healthcare & Bio
topic_mentionALGSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001193125-26-092614EDGAR99K words
2025-03-102024-12-310000950170-25-035929EDGAR—
2024-03-122023-12-310000950170-24-029953EDGAR—
2023-03-092022-12-310000950170-23-007033EDGAR—
2022-03-102021-12-310000950170-22-003365EDGAR—
2021-03-232020-12-310001564590-21-014872EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-268203EDGAR71K words
2025-08-062025-06-300000950170-25-104042EDGAR—
2025-05-062025-03-310000950170-25-063983EDGAR—
2024-11-062024-09-300000950170-24-122371EDGAR—
2024-08-062024-06-300000950170-24-091828EDGAR—
2024-05-072024-03-310000950170-24-054497EDGAR—
2023-11-022023-09-300000950170-23-058256EDGAR—
2023-08-032023-06-300000950170-23-038045EDGAR—
2023-05-042023-03-310000950170-23-017890EDGAR—
2022-11-022022-09-300000950170-22-021248EDGAR—
2022-08-042022-06-300000950170-22-014815EDGAR—
2022-05-042022-03-310000950170-22-007407EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001171843-26-001340EDGAR3K words
2026-02-040001193125-26-037558EDGAR—
2025-11-060001171843-25-007075EDGAR—
2025-08-060001171843-25-005116EDGAR—
2025-06-260001193125-25-148905EDGAR—
2025-05-060001171843-25-002781EDGAR—
2025-03-100001171843-25-001352EDGAR—
2025-02-120001193125-25-024838EDGAR—
2025-02-030001193125-25-019256EDGAR—
2024-11-060001171843-24-006057EDGAR—

84 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001799448
TickerALGS
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 346e784e5c208ddfc5476432a04b24141513ab715c7d03ca746c6da91539495b
parent: 1fa93ea31e40118857106f1c9cdfa552ac7c04316ab1752783a30fd0265f1240
content hash: 6b9eeaffa0f5f5713199831734b6a525c407e9002174762d1c456095aa8e35f1
signed: 2026-04-13T04:43:35.135Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf